Gene Therapy Starting Materials Market To Reach $5.40 Billion By 2030

Gene Therapy Starting Materials Market Growth & Trends

The global gene therapy starting materials market size is anticipated to reach USD 5.40 billion by 2030 and is projected to grow at a CAGR of 19.24% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is driven by increasing demand for high-quality raw materials to support the expanding pipeline of gene therapies targeting rare and genetic disorders, cancer, and other complex conditions. As more therapies advance through clinical trials and gain regulatory approvals, the need for scalable, GMP-compliant plasmids, viral vectors, and other key inputs continues to rise.

Furthermore, technological advancements, growing R&D investments, and supportive regulatory frameworks are further accelerating the market. In addition, partnerships between biotech firms and manufacturers are enhancing production capabilities and ensuring a consistent supply chain, positioning the gene therapy starting materials industry for strong and sustained growth through the forecast period.

The COVID-19 pandemic further accelerated the demand for gene therapy starting materials by highlighting the need for rapid therapeutic development and scalable manufacturing. It spurred investments in advanced bioproduction infrastructure and increased focus on genetic platforms, driving growth in plasmid DNA, viral vectors, and other critical components used in both vaccine and gene therapy development.

In addition, the expanding pipeline of gene therapies has further fueled market growth. As more therapies advance into clinical trials and receive regulatory approvals, the demand for high-quality starting materials such as plasmid DNA and viral vectors continues to rise. This has prompted increased investments in manufacturing capacity, advanced technologies, and strategic partnerships, enabling efficient scale-up and supply to meet the evolving needs of gene therapy developers worldwide.

However, strict regulatory requirements for safety, quality, and compliance can delay the development and approval of gene therapy products. While essential for ensuring patient safety, these regulations often involve complex documentation, extensive testing, and prolonged review timelines. This can slow market entry, increase operational costs, and create barriers for smaller companies with limited regulatory expertise. As the industry evolves, navigating these requirements remains a critical challenge for stakeholders in the gene therapy starting materials market.

 Request a free sample copy or view report summary: Gene Therapy Starting Materials Market Report

Gene Therapy Starting Materials Market Report Highlights

• The viral vectors segment led the market with the largest revenue share of 42.91% in 2024, owing to their high efficiency in gene delivery and widespread use in approved gene therapies. However, the plasmid DNA segment is expected to grow at the fastest CAGR of 20.13% over the forecast period.

• Based on development stage, the clinical therapeutics segment accounted for the largest market share in 2024, driven by the growing number of gene therapy candidates advancing through clinical trials. On the other hand, the pre-clinical therapeutics segment is expected to witness at the fastest CAGR over the forecast period.

• Based on application, the oncology segment accounted for the largest revenue share in 2024 and is anticipated to grow at the fastest CAGR over the forecast period, attributed to the rising prevalence of cancer, strong clinical pipeline, and increasing adoption of gene therapies targeting various tumor types. However, the genetic disease segment is projected to grow at a significant CAGR over the forecast period.

• Based on end use, the biopharmaceutical and pharmaceutical companies segment accounted for the largest market revenue share in 2024, driven by increased investment in gene therapy R&D, in-house manufacturing capabilities, and strategic partnerships to accelerate therapy development. On the other hand, the CROs & CMOs segment is expected to register at the fastest CAGR during the projected period.

• North America dominated the market with the largest revenue share in 2024 due to strong R&D investment, advanced manufacturing capabilities, and a high concentration of industry leaders. The Asia Pacific region is expected to grow at the fastest CAGR during the forecast period.

Gene Therapy Starting Materials Market Segmentation

Grand view research has segmented the gene therapy starting materials market based on product, development stage, application, end use, and region:

Gene Therapy Starting Material Product Outlook (Revenue, USD Billion, 2018 - 2030)

• Viral Vectors

  • Adenovirus

  • Retrovirus

  • Adeno-Associated Virus (AAV)

  • Lentivirus

  • Others

• Plasmid DNA

• Cell Lines

• Others

Gene Therapy Starting Material Development Stage Outlook (Revenue, USD Billion, 2018 - 2030)

• Pre-clinical Therapeutics

• Clinical Therapeutics

• Marketed Therapeutics

Gene Therapy Starting Material Application Outlook (Revenue, USD Billion, 2018 - 2030)

• Oncology

• Infectious Disease

• Genetic Disease

• Others

Gene Therapy Starting Material End Use Outlook (Revenue, USD Billion, 2018 - 2030)

• Biopharmaceutical & Pharmaceutical Companies

• CROs & CMOs

• Others

Gene Therapy Starting Material Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Sweden

  • Denmark

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • UAE

  • Saudi Arabia

  • Kuwait

List of Key Players in the Gene Therapy Starting Material Market

• Charles River Laboratories

• GenScript

• Thermo Fisher Scientific, Inc.

• Lonza

• Catalent

• Eurofins Scientific

• Danaher

• Merck KGaA

• Revvity, Inc.

• Sartorius AG